The Stargardt disease therapeutics market is focused on developing innovative gene therapy approaches to address the unmet needs in this retinal disease segment. Stargardt disease, also called fundus flavimaculatus or Stargardt macular dystrophy, is the most common form of juvenile macular degeneration that causes central vision loss due to abnormal accumulation of lipofuscin in the retinal pigment epithelium. Therapeutics in the Stargardt disease segment are aimed at developing therapies that can provide better visual acuity or alter disease progression.
Global stargardt disease therapeutics market is estimated to be valued at US$ 213.5 Mn in 2023, and is expected to exhibit a CAGR of 31.7% during the forecast period (2023-2030).
Key players operating in the Stargardt disease therapeutics market are Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc., Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd, ReVision Therapeutics, Inc. and Lin BioScience, Inc.
Key Takeaways
- Key players like Kubota Pharmaceutical Holdings, Iveric Bio and Stargazer Pharmaceuticals are developing gene therapy and small molecule approaches for Stargardt disease.
- Increasing prevalence of age-related macular degeneration and other retinal diseases is expected to drive the demand for Stargardt disease treatment options.
- Companies are also exploring opportunities in Asia Pacific and Latin American markets to increase their geographic footprint and tap into high growth markets.
Market Key Trends
Gene therapy is emerging as a promising therapeutic approach for Stargardt disease with companies like Iveric Bio and Kubota Pharmaceutical Holdings conducting clinical trials for gene therapy candidates. These therapies work by delivering a normal version of the faulty gene to restore the function of retinal pigment epithelium cells and decrease lipofuscin accumulation. If successful, gene therapies can provide durable treatment outcomes for Stargardt disease patients.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the Stargardt Disease Therapeutics Market Growth is moderate as significant investment capital is required to develop a drug along with clinical trials. Bargaining power of buyers: The bargaining power of buyers is moderate as there are limited treatment options available for Stargardt Disease. Bargaining power of suppliers: The bargaining power of suppliers is moderate as suppliers have standard supply contracts with manufacturers and development is a long process. Threat of new substitutes: The threat of new substitutes is low as there are limited treatment options available for Stargardt Disease. Competitive rivalry: The competition in the market is high as key players are focusing on developing novel therapies.
Geographical regions
North America accounts for the largest share of the global Stargardt Disease therapeutics market in terms of value owing to growing prevalence rates of Stargardt Disease in the region and presence of major players. Europe is the second largest market due to availability of favourable reimbursement policies and increasing research funding for rare diseases.
Asia Pacific region is expected to show the fastest growth over the forecast period in the global Stargardt Disease therapeutics market due to rising healthcare expenditure, growing awareness about rare diseases and increase in disposable income. In addition, improving healthcare infrastructure and presence of less stringent regulations for approval of drugs is further supporting market growth in Asia Pacific.
Get more insights on - Stargardt Disease Therapeutics Market
Discover the Report for More Insights, Tailored to Your Language.
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Comments on “Stargardt Disease Therapeutics Market is Fueled by Innovative Gene Therapy Approaches”